Mr. Elad Bibi-Aviv reports

SEEGNAL SUCCESSFULLY INITIATES FIRST U.S. PILOT PROGRAM

Seegnal Inc. has successfully initiated its first pilot program in the United States, following the letter of intent, announced on May 19, 2026.

The pilot program is being conducted with a United States-based long-term care provider and is expected to run between eight and 12 weeks from the receipt of data, followed by a potential extended evaluation period.

Approximately 1.2 million Americans live in CMS-certified nursing facilities, a population characterized by advanced age, multiple chronic conditions and high rates of polypharmacy. Adverse drug events are a significant and often preventable source of hospitalization in this population: an estimated 99,628 emergency hospitalizations each year in U.S. adults aged 65 and older are attributable to adverse drug events.

"Initiating this pilot is an important step in executing on our U.S. commercial strategy," said Elad Bibi-Aviv, chief executive officer of Seegnal. "Long-term care is a setting where medication complexity, polypharmacy and the need for individualized prescribing decisions converge. These are areas where our platform was designed to add value.

"We look forward to working with our pilot partner and to reporting on progress in due course."

About Seegnal Inc.

Seegnal is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The company's software-as-a-service-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing and advance a more personalized standard of patient care. Seegnal's technology is deployed across health care settings and is used by more than 15,000 clinicians in daily practice.

We seek Safe Harbor.